期刊文献+

心内科"生命网"讲座中调查问卷的使用 被引量:2

Utilize Questionnaires in "Heart care network" of Cardiac Outpatients
下载PDF
导出
摘要 目的:通过在心内科"生命网"讲座中调查问卷的使用,分析患者的现状,探讨"生命网"在冠心病一级预防和二级 预防中的临床意义。方法:在"生命网"讲座中发放调查阅卷,询问患者的血压、血脂、血糖等危险因素情况及其药物治 疗,并及时了解患者的要求与意见。结果:在82例参加"生命网"讲座的患者中,收回62份问卷,反馈率为75.61%。患者 血压的知晓率为83.87%;血脂的知晓率为80.64%;血糖的知晓率54.84%。各种危险因素的控制情况为:血压中收缩压、 舒张压的达标率分别为86.54%、96.15%;血糖的达标率为85.29%。在心肌梗死的亚组中,93.33%患者接受抗血小板治 疗,86.67%患者接受降脂治疗,43.33%患者接受ACEI或ARB类药物的治疗;90.00%患者接受β-阻滞剂的治疗。结论: 在心内科"生命网"讲座中,使用调查问卷可以快速了解患者的现状,了解患者危险因素的检测、治疗与达标,并及时反馈 患者的需求,提高医患之间的互动性。 Objective:We utilize questionnaires in 'Heart care network'of cardiac outpatients, analyze patients'current status, discuss clinical meanings of 'Heart care work' in primary and secondary prevention of coronary artery diseases. Methods: We provided quesuonnaires for cardiac outpatients who attended lectures, inquired risk fectors(blood pressure, lipid, glucose, smoking) and treatments of patients, realized demands and opinions. Results: Among 82 patients who attended lectures, 75.61% returned the questionnaires.Of those patients, 83,87% learned their blood pressure, 80.64% learned their lipid, 54.84% learned their glucose. During controlling different risk factors, 86.54% patients reached systolic pressure standard, %.15%patients reached diastolic pressure standard, 85.29%reached glucose standard. In myocardial infraction subgroup, 93.33% patients received antiplatelet therapies, 86.67% patients received lipid-lowering treatments,43.33% patients took ACEI or ARB drugs;90.00% received β-adrenergic receptor blockers. Conclusion: During lectures of 'Heart care network ', utilization of questionnaires can quickly learn current status of patients, learn detection, treatment, reaching goals of risk factors, and feedback demands of patients,improve interactions.
出处 《中国医药导刊》 2005年第2期90-91,108,共3页 Chinese Journal of Medicinal Guide
关键词 心内科 生命网 讲座 调查问卷 二级预防 Heart care network questionnaire secondary prevention
  • 相关文献

参考文献11

  • 1胡大一,李奎宝.口服华发林抗凝治疗中出血并发症危险因素的病例对照研究[J].中国医药导刊,2004,6(1):41-44. 被引量:22
  • 2《中国高血压防治指南》修订编委会.中国高血压防治指南[Z].,2004年修订版,2004年9月..
  • 3Standards of medical care for patients with diabetes mellitus.Diabetes Care,2003;26:S33~S50.
  • 4郭兰.冠心病人的心脏康复治疗和生命网[J].中国医药导刊,2004,6(5):389-390. 被引量:11
  • 5Sueta CA, Choolhury M, Boocuzi SJ, et al. Analysis of the degree of undertreatmnet of hyperlipidemia and congestive heart failure secondary to coronary heart diaese. Am J Cardiol, 1999;83:1303~1307.
  • 6Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med,2000;160:459~467.
  • 7Antiplatelet Trialist's Collaboration. Collaborative overview of randomizaed trial of antiplatelet therapy. Prevention of death.Myocardial infarction and strike by prolonged antiplatelet therapy in various categories of patients. BMJ, 1994;308:81~106.
  • 8Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agnets in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J,2004;25:166~181.
  • 9ESC expert consensus document on β-adrenergic receptor blockers. The task force on beta-blockers of the European Society of Cardiology. Eur Heart J,2004;25:1341~1362.
  • 10Anbe DT, Armstrong PW, Bates ER, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction-Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation,2004;110:588~636.

二级参考文献12

  • 1Fuster V, Ryden LE, Asinger RW, et al.ACC/ AHA Practice Guidelines.Circulation, 2001; 104:2118.
  • 2Abdelhafiz AH. A review of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation. Clin Ther, 2001 ; 23 ( 10 ) : 1628 - 1636.
  • 3Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med, 1994; 120:897 - 902.
  • 4Gorter JW. Major bleeding during anticoagulation after cerebral ischemia:patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT) . European Atrial Fibrillation Trial (EAFT) study groups.Neurology,1999; 53: 1319-1327.
  • 5Chenhsu RY, Chiang SC, Chou MH, et al. Long - term treatment with warfarin in Chinese population. Ann Pharmacother, 2000; 34:1395 1401.
  • 6Copland M, Walker ID, Tait RE. Oral anticoagulation and hemorrhagic complication in an elderly population with atrial fibrillation. Arch Inten Med, 2001 ; 161 : 2125 - 2128.
  • 7Beyth BJ, Landefeld CS. Outcomes of warfarin the rapy: lessons from thereal world[Editorial] .Mayo Clin Proc, 1995;70:806-808.
  • 8Saour JN, Sieck JO, Mamo LA, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med, 1990; 322:428 - 432.
  • 9Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a rtmta - analysis. Ann Intern Med, 1999; 131:492 - 501.
  • 10Hansson L, Zanchetti A, Carruthers G, et al. Effects of intensive blood →pressure lowering and low - dose aspirin in patients with hypertension :principal results of the Hypertension Optimal Treatment (HOT) randomiseed tral. lancet. 1998:351:1755 - 1762.

共引文献31

同被引文献18

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部